AI in Wound Care Market

The global AI in wound care market generated USD 580.0 million in 2025 and is estimated at USD 659.3 million in 2026. At 13.7% annual growth, supplier revenue is projected to reach USD 1,839.0 million by 2034. The defined market covers wound-specific AI software, algorithm-enabled imaging devices and licensed decision-support services; ordinary dressings, clinical consultation fees and general electronic health records are excluded.

AI-assisted wound assessment combines smartphone photography, computer-vision segmentation, measurement algorithms and clinician-facing dashboards. eKare inSight measures wound dimensions without a reference marker, while Swift Skin & Wound connects bedside imaging with documentation and remote review. These products compete for hospital subscriptions and care-network contracts rather than revenue from dressings or debridement procedures. Wound imaging is only one part of care: clinicians still evaluate vascular supply, infection, pressure relief and underlying disease before choosing a treatment. Reliable serial measurements can help teams identify patients who need an earlier appointment.

The International Diabetes Federation estimated 589 million adults aged 20–79 were living with diabetes in 2024, a major pool of patients at risk of foot complications. The CDC reported 40.1 million US residents with diabetes in its September 2026 statistics update. Neither figure is an annual wound count, and only a subset of people with diabetes develop ulcers. Procurement therefore depends on the number of active wound-care encounters, clinical staffing and integration with existing records, rather than the diabetes population alone. Community providers may favor smartphone capture over dedicated imaging carts.

Regulatory pathways differ across the 2026 commercial offerings from Spectral AI and Pixacare. Spectral AI received US FDA De Novo authorization for its DeepView burn assessment system on 26 May 2026, whereas Pixacare describes WoundTrack II as a CE Class IIa module for chronic-wound surface and tissue analysis. Registration, certification and marketing authorization are not interchangeable; each system must be used within its intended indications. The 2024 WISDOM AI surgical-wound study reported 89% sensitivity for prioritizing cases but also identified performance differences across skin tones. Those findings support monitored clinical use rather than autonomous wound diagnosis.

Commercial value is shifting toward longitudinal records that clinicians can share across settings. In April 2025 eKare announced a 12-month Oxford Health NHS Foundation Trust initiative using inSight for wound assessment and monitoring. Net Health's Tissue Analytics platform connects wound images with clinical dashboards, and Intellicure launched iMeasure.ai in 2025 for automated measurement integrated with wound charting. The 2026–2034 outlook assumes further adoption of these software and integrated imaging products; the regional and segment allocations are directional 2025 estimates, not independently audited supplier sales splits.

Source: IDF Diabetes Atlas; CDC diabetes statistics; Spectral AI authorization; WISDOM clinical evaluation.

Supplier revenue is attributed to wound-specific algorithm software, automated measurement platforms, predictive imaging systems and associated recurring licenses. A wound visit is not counted as platform revenue merely because an algorithm is used. Hardware is included only where it forms part of a dedicated AI wound imaging product; the sale of dressings, generic cameras and unrelated EHR modules is outside the boundary.

Drivers Impact Analysis*

Restraints Impact Analysis*

*CAGR contribution shows the percentage points each factor adds to or removes from the 13.7% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

Diabetes complications increase repeat measurement and follow-up needs

The IDF reported 589 million adults living with diabetes in 2024, while WHO identified substantial treatment gaps in low- and middle-income countries. Foot ulceration is a serious but non-universal complication, so wound-specific demand is tied to active clinical episodes rather than the full diabetes population. Repeated photographs and standardized measurements can document whether an ulcer is shrinking between visits. Platforms such as eKare inSight and Intellicure iMeasure.ai seek to replace ruler-based workflows with structured records, creating software value when clinics can demonstrate improved assessment consistency.

Hospital documentation requirements support integrated image analytics

US hospitals and post-acute providers must distinguish wounds present on admission from injuries acquired during care, which makes dated images and consistent measurements valuable. Net Health Tissue Analytics offers centralized wound images and dashboards, while Perceptive Solutions connects WoundZoom measurements with clinical records. Data entry must fit existing nurse workflows or additional screens can erode the promised time savings. Buyers therefore evaluate interoperability, audit trails and access controls alongside algorithm performance, and enterprise contracts may require implementation work before recurring license revenue begins.

Remote clinical review extends specialist reach across dispersed care sites

Healthy.io Minuteful for Wound supports consistent imaging and remote clinical guidance, while Swift Medical provides centralized reports across patients and care teams. The April 2025 Oxford Health initiative with eKare illustrates a provider-led assessment of digital wound management outside a single specialist department. Remote capture may reduce unnecessary travel when images are interpretable and triage protocols are clear, but worsening infection or ischemia still requires in-person evaluation. Reimbursement, device availability and broadband reliability affect how quickly home-health organizations deploy these services.

Burn-specific regulatory authorization opens a differentiated device pathway

Spectral AI announced FDA De Novo authorization for DeepView's burn indication on 26 May 2026. Its multispectral imaging and algorithm classify areas unlikely to heal within 21 days, addressing a different decision from routine chronic-ulcer area measurement. The company applied for a CMS New Technology Add-On Payment in October 2026, with a decision expected in 2027. An authorization permits marketing for the cleared indication but does not guarantee hospital purchasing or payment. This distinction limits immediate revenue while creating a regulated product category for specialized burn centers.

Source: IDF Diabetes Atlas 2025; CDC September 2026; eKare Oxford Health April 2025; Net Health Tissue Analytics; Spectral AI FDA authorization May 2026.

Image segmentation expands from area measurement to tissue characterization

Pixacare's WoundTrack II combines surface measurement with estimates of granulation, fibrin and necrotic tissue proportions under a CE Class IIa framework. eKare's healBot is embedded in its inSight environment to help users explore wound data and clinical information. These functions differ in evidentiary requirements: a measurement claim needs validation against reference methods, while a treatment recommendation may trigger additional regulatory obligations. Buyers increasingly request transparent confidence metrics, consistent lighting and reproducible photography before permitting algorithm output into clinical decision-making.

Enterprise procurement favors integration rather than isolated mobile applications

Intellicure offers SMART-on-FHIR integration with hospital record systems and introduced iMeasure.ai in 2025. Swift Medical describes a connected portal for risk monitoring and reimbursement documentation, while Net Health Tissue Analytics links imaging to centralized dashboards. Hospitals may prefer a single vendor responsible for secure image transfer, patient matching and support across sites. This favors enterprise contracts but creates longer implementation cycles and staff retraining, especially where clinical photography previously lived in local folders or unstructured EHR attachments.

Clinical studies increasingly examine bias and real-world triage outcomes

The 2024 WISDOM surgical-wound AI study reported 89% sensitivity for identifying cases requiring priority review, yet found variations in recognizing wound characteristics across skin tones. A 2025 systematic review of chronic-wound AI highlighted the need for external validation and clinical workflow testing. Device vendors must therefore demonstrate performance beyond curated image datasets and monitor errors after deployment. Prospective studies, subgroup reporting and clinician override controls can influence hospital procurement more than headline accuracy values measured under laboratory conditions.

Solution categories are based on the primary commercial deliverable, not every feature visible on a screen. Image measurement licenses, predictive clinical decision systems and remote triage platforms each receive a separate supplier-revenue assignment. Integrated subscriptions are assigned by the contracted principal service so the three classes remain exclusive.

Measurement products lead where encounter frequency justifies subscription cost, while specialized prediction systems may command higher per-installation prices. Remote monitoring requires clear clinical escalation rules and secure consent processes to convert digital access into measurable care capacity.

Applications classify the clinical purpose of the wound-care encounter: longitudinal chronic-ulcer assessment, surveillance of acute or postoperative wounds, and burn healing prediction. A single patient's separate episodes can enter different categories, but a given licensed assessment is allocated once to its primary indication.

Clinical application boundaries follow the device-specific intended uses documented by Spectral AI and Pixacare. Buyers should compare evidence within each wound type because an algorithm validated for burns cannot automatically claim comparable performance in diabetic ulcers or postoperative wounds.

Purchasing institutions are divided into hospital and specialist wound centers, community or home-health organizations, and long-term care facilities. The patient's physical location at the moment of imaging does not change the buyer classification; a hospital-operated home-monitoring program remains hospital revenue.

Enterprise networks can span all three care settings, yet each invoice is assigned to the contracting institution. Procurement success depends on workflow continuity and clinical accountability rather than solely on the number of photographs uploaded.

Vendor invoices determine whether AI wound-care revenue arises from an enterprise subscription, a metered site or use license, or an integrated device sale. These are financial contract types rather than clinical functions, and a bundled system is allocated to one category to prevent duplicate counting.

Recurring software may expand as more users access existing imaging workflows, whereas integrated devices remain sensitive to capital budgets and clinical approvals. The financial split follows recognized supplier contracts, not patient reimbursement receipts.

Regional adoption reflects chronic-disease burden, availability of trained wound clinicians, data-protection rules and the maturity of hospital software procurement. The five region allocations are directional 2025 revenue estimates and total 100%; country examples describe demand conditions rather than independently audited national AI wound-care sales.

AI wound software is usually purchased through hospital, clinic or care-network technology budgets rather than reimbursed as a separate drug or dressing. For DeepView, FDA authorization occurred in May 2026, while the CMS payment application followed in October. For example, Spectral AI applied for an inpatient New Technology Add-On Payment in October 2026 after receiving De Novo authorization, but CMS had not yet decided the application. Contract negotiations therefore focus on total clinical workflow cost, integration and documented patient outcomes.

The 2026 DeepView NTAP application illustrates the separation between regulatory authorization and reimbursement. Spectral AI said it expected a CMS determination in August 2027, with potential payments from October 2027 if approved. Hospitals cannot assume that a new device will receive extra inpatient funding. For chronic-ulcer platforms, return on investment is more often evaluated through documentation time, patient follow-up and avoidable visits. Supplier-provided efficiency claims require local validation because staffing mix and EHR workflows differ between facilities.

A health system purchasing image analysis across multiple facilities must decide who owns photographs, who can access them and how they are retained. Swift Medical and Net Health emphasize EHR-connected wound records, while Pixacare highlights protected clinical image capture outside personal photo galleries. Deployment may require staff education on lighting, distance and image calibration. In home care, delayed synchronization and patient consent can affect the reliability of serial comparisons, so vendors need offline workflows and escalation protocols.

European procurement is also influenced by the intended use and classification of the software module. Pixacare describes WoundTrack II as a CE Class IIa device for adult chronic wounds within a defined size range, not as a universal wound diagnostic. The MHRA's June 2026 AI Airlock report addresses broader testing of AI medical devices, including real-world safety and performance. Purchasers should distinguish an algorithm's documented clinical claim from a general data-visualization feature before assigning risk and training obligations.

Source: Spectral AI NTAP filing; MHRA AI Airlock.

Regulatory review applies to the intended medical purpose of each algorithm, not to every feature marketed as AI. Burn-healing prediction, automated chronic-wound measurement and administrative documentation can fall under different requirements. Clinicians must know whether a tool supplies a measurement, a triage priority or a diagnosis, and whether the relevant authority has cleared that specific claim.

Spectral AI's DeepView combines multispectral imaging and machine learning to identify burn regions unlikely to heal within 21 days. The FDA De Novo decision announced in May 2026 permits US commercialization for the authorized indication. In October the company began a UK clinical study aimed at expanding the label to burns of the head, hands and feet, showing that existing authorization does not automatically include every anatomical site. Burn teams must continue clinical assessment and treatment planning rather than delegating operative decisions to an algorithm.

Pixacare's WoundTrack II is described as a CE Class IIa module that calculates chronic-wound area and tissue proportions from calibrated images. Its public product information specifies adult lesions of 4–100 square centimeters. That intended-use statement differs from a device predicting burn healing or detecting infection. A 2025 systematic review of chronic-wound AI found substantial methodological variation, reinforcing the need for externally validated datasets and transparent performance metrics. Device claims must be assessed separately from general documentation software.

The WISDOM surgical-wound study found 89% sensitivity for identifying cases needing priority review, but sensitivity for some features differed across skin tones. Algorithm developers need representative training data, subgroup analysis and prospective testing after deployment. The UK MHRA published its second AI Airlock report in June 2026, describing case studies and regulatory lessons for AI as a medical device. Those initiatives can guide evaluation practices, but they do not confer marketing authorization on unrelated wound-care applications.

Competition includes software-first wound documentation providers, integrated imaging systems and algorithm-driven clinical prediction products. Contracts differ in whether the vendor supplies a smartphone workflow, a cloud dashboard, a dedicated optical sensor or a regulated clinical decision output. Buyers compare validated measurement performance, interoperability and service coverage rather than treating every product labeled AI as a direct substitute.

Pixacare competes through its CE Class IIa WoundTrack II module and secure smartphone documentation. Its published intended use focuses on adult chronic-wound surface and tissue analysis, and the company reports adoption in European hospitals. Intellicure's iMeasure.ai integrates automated measurement with specialist wound charting and SMART-on-FHIR connections. Both vendors can enter accounts already using an established EHR, but their differentiation depends on clinical workflow and validated measurements rather than generic cloud storage.

Perceptive Solutions markets WoundZoom, combining automated wound dimensions, depth assessment and record synchronization. Its WoundZoom PRO launch described an AI algorithm for three-dimensional wound topography. KroniKare in Singapore combines multispectral sensing and machine learning for chronic wound classification, giving it a different hardware profile from phone-only tools. These systems may serve organizations requiring richer imaging data, although equipment maintenance and staff training add cost.

imitoWound provides validated mobile wound measurement and integration with hospital records, with treatment-oriented AI described as an upcoming feature rather than an established approved diagnostic. Brazil's LAiCare markets AI-based wound assessment, protocol support and specialist review for care networks. Their regional opportunities depend on language, procurement pathways and local clinical validation. A vendor's broad geographic availability should not be equated with disclosed wound-AI revenue or a uniform regulatory authorization.

The 2024 WISDOM study and 2025 reviews of diabetic-foot algorithms emphasize the need for representative images, external validation and real-world evaluation. A product that performs well on a curated dataset may struggle with different lighting, skin pigmentation or wound types. Suppliers that document failure modes, allow clinician override and support audit-ready longitudinal records may secure renewals, while unvalidated autonomous treatment claims face regulatory and clinical resistance.

• eKare
• Swift Medical
• Healthy.io
• Spectral AI
• Net Health
• Pixacare
• Perceptive Solutions
• Intellicure
• KroniKare
• imito
• LAiCare

The AI in wound care market is projected to rise from USD 659.3 million in 2026 to USD 1,839.0 million in 2034, with a 13.7% CAGR. The forecast follows the publisher's reported 2024, 2025 and 2032 values, extended to the 2026–2034 period. It is not an independently audited aggregation of vendor sales, and the segment shares remain directional estimates.

The chronic-ulcer category is expected to retain the largest clinical application allocation because patients with diabetic foot, venous leg and pressure injuries often require repeated assessment. IDF's 2024 diabetes estimate and the CDC's 2026 US statistics indicate a substantial population at risk, but not every person with diabetes needs wound care. The commercial opportunity comes from active patient encounters, trained clinicians and repeat use of standardized images. Vendors with secure longitudinal records may win renewals when they reduce fragmented documentation and allow timely specialist escalation.

Regulated prediction tools could create a higher-value segment distinct from routine measurement. DeepView's May 2026 FDA authorization gives Spectral AI a burn-specific commercial route, while its October 2026 NTAP application remains subject to CMS review. Hospital procurement may accelerate if clinical outcomes and payment support are demonstrated, but a favorable regulatory decision alone does not ensure adoption. Developers of other algorithms must validate their intended indications rather than relying on broad claims about artificial intelligence in wound management.

Care-network software will compete on integration, clinical accountability and the ability to capture usable images in real settings. eKare's Oxford Health demonstration, Intellicure's 2025 iMeasure.ai launch and Pixacare's European CE-marked module illustrate distinct routes to provider adoption. Community and long-term care teams require simple capture methods and remote review, whereas hospital IT departments require audit logs, data protection and reliable patient matching. These needs support subscription demand but also raise implementation and training expenses.

Uncertainty remains around external validity, reimbursement and local purchasing capacity. The 2024 WISDOM study found sensitivity differences across skin tones, and 2025 reviews of chronic-wound AI called for more prospective evidence. Procurement committees may delay decisions if an algorithm has limited validation outside its development dataset. Across regions, disease burden is not a substitute for measured software sales. The forecast therefore depends on clinical evidence, responsible use, payer policies and supplier execution rather than assuming universal adoption of every available tool.

Coverage measures wound-specific AI software and integrated devices at supplier revenue level, with no double counting of dressings, clinical visits or generic EHR contracts. The report distinguishes intended indications, commercial settings and payment models across five geographic regions.